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As of 25 March 2015, the largest recorded outbreak of Ebola virus infection is ongoing, with almost 25 000 cases
and >10 000 deaths. There are 5 genetically and antigenically distinct species within the genus Ebolavirus. Lim-
ited cross-reactivity and protection is observed between these 5 Ebolavirus species, which complicates vaccine
development. However, on the basis of sequence homology between the 5 Ebolavirus species, we hypothesize that
conserved epitopes are present on the viral glycoprotein (GP), which can be targeted by antibodies. In the
current study, a panel of mouse monoclonal antibodies was isolated and characterized using an enzyme-linked
immunosorbent assay (ELISA) to determine cross-reactivity, avidity, and competition for epitope binding;
Western blot analysis was also performed. Four monoclonal antibodies were identiﬁed by ELISA as cross-
reacting with the GPs of all 5 Ebolavirus species. The identiﬁcation of cross-reactive antibodies that bind the
GPs of all known Ebolavirus species will give us important insight into the presence of conserved epitopes
on the viral GP. These data will be crucial for the development of novel therapeutics and diagnostic assays.
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Ebola virus (EBOV) is an emerging pathogen belonging
to the genus Ebolavirus in the family Filoviridae and is
the causative agent of Ebola virus disease [1]. As of 25
March 2015, the largest recorded outbreak of EBOV
infection is ongoing, with 24 907 cases and 10 326
deaths [2].
There are 5 genetically and antigenically distinct spe-
cies of Ebolavirus: Bundibugyo virus (BDBV), Taï For-
est virus (TAFV), Reston virus (RESTV), Sudan virus
(SUDV), and EBOV [1]. Limited cross-reactivity and
cross-protection are observed among these 5 Ebolavirus
species, which complicates development of vaccines
and diagnostic tests. The Ebolavirus glycoprotein (GP)
mediates viral attachment and entry into host cells and
is a major target for the host immune response [3]. Sev-
eral candidate vaccines are in development, most of
which use the GP as the immunogen [4]. Vaccination
with GP results in a robust antibody response, which
has recently been shown to be a mechanism of protec-
tion in nonhuman primates [5, 6]. The development
and characterization of monoclonal antibodies
(mAbs) has been instrumental in identifying neutraliz-
ing epitopes [7, 8]; however, most neutralizing antibod-
ies are Ebolavirus-species speciﬁc and do not cross-
react. Therefore, a mix of several mAbs are needed for
broad protection against infection and disease.
We previously identiﬁed a mAb (S9) that binds the
EBOV GP and neutralizes EBOV but not the other 4
Ebolavirus species in vitro. In addition, this mAb protects
in vivo against EBOV infection [9]. However, based on
the sequence homology among the 5 Ebolavirus species,
we hypothesized that conserved epitopes are present on
the Ebolavirus GPs, which can be targeted by antibodies.
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In the current study, we characterized a panel of mAbs that rec-
ognize the GP of all known Ebolavirus species.
METHODS
mAbs were previously generated by vaccinating mice with re-
combinant vesicular stomatitis virus (rVSV) expressing the
EBOV GP (rVSV-EBOV-GP) and inducing a cross-reactive
memory response by boosting with the heterologous rVSV-
SUDV-GP as previously described [9]. rVSV was kindly provid-
ed by Dr Andrea Marzi. Brieﬂy, 3 days after boost, hybridoma
cells were generated by fusing mouse plasma cells with SP2/0-
Ag14 myeloma cells (ATCC) and were selected using HAT/HT
selection medium. Monoclonal hybridoma cells were isolated
by performing 2 rounds of limiting dilutions in 96-well
ﬂat-bottomed tissue culture plates. Isolated hybridoma cells
were initially screened by enzyme-linked immunosorbent
assay (ELISA) for detection of secreted antibodies, using a solu-
ble, transmembrane-deleted, trimeric glycoprotein of EBOV,
SUDV, RESTV, TAFV, and BDBV as previously described
[9, 10]. Plasmids encoding for soluble, transmembrane-deleted
GP were kindly provided by Dr Ayato Takada.
Approval for animal experiments was obtained from the
institutional animal care and use committees at the Rocky
Mountain Laboratories, Division of Intramural Research, Na-
tional Institute of Allergy and Infectious Diseases, National In-
stitutes of Health (NIH), and the University of Texas Medical
Branch. Animal work was performed by certiﬁed staff in an As-
sociation for Assessment and Accreditation of Laboratory
Animal Care–approved facility. Animal housing, care, and ex-
perimental protocols were in accordance with NIH guidelines.
RESULTS AND DISCUSSION
A total of 33 monoclonal hybridoma cells produced antibodies
that bound the GP of ≥1 Ebolavirus species (data not shown).
All mAbs that bound EBOV GP were subsequently tested in a
plaque reduction assay as previously described [9]. With the
exception of the previously published S9 mAb, none of the
other mAbs neutralized any of the Ebolavirus species (data
not shown). In the absence of neutralizing activity, the focus
was shifted to cross-reactive mAbs that can bind to all
known Ebolavirus species. ELISA identiﬁed 4 immunoglobu-
lin G1 mAbs (S3, S12, S17, and S33) that bound the GPs of all
5 Ebolavirus species, although the reactivity of S3 was typically
lower than that of S12, S17, and S33 (Figure 1A–D). This sug-
gested that ≥1 conserved epitope on the GP was targeted by
these mAbs.
Figure 1. Cross-reactivity of monoclonal antibodies (mAbs) against 5 Ebolavirus species. The reactivity of the 4 mAbs S3 (A), S12 (B), S17 (C), and S33 (D)
was determined by an enzyme-linked immunosorbent assay, using the soluble glycoprotein of Bundibugyo virus (BDBV), Taï Forest virus (TAFV), Reston virus
(RESTV), Sudan virus (SUDV) and Ebola virus (EBOV) as antigens.
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To determine whether linear or conformational epitopes
were targeted, mAbs underwent Western blotting to detect
the GP of the 5 different Ebolavirus species, as previously de-
scribed [9]. Surprisingly, while ELISA found that all mAbs
cross-reacted, Western blotting revealed that only S33 and S17
detected the GP1 from the 5 different species and that S3 and
S12 only bound the EBOV GP (data not shown). Detection of
the EBOV GP suggests that the mAbs recognized ≥1 linear epi-
topes on the GP1 but that these epitopes are only partially con-
served, since the same epitope on the GP of other Ebolavirus
species was not always detected.
To determine whether the difference in Western blot ﬁndings
among the Ebolavirus species could be due to differences in the
avidity of the mAbs for the GP epitopes of the 5 species, we
adapted the ELISA. Brieﬂy, a 5-minute incubation step with
or without 8 M urea was added after aspiration of the mAbs,
and the avidity index was calculated as previously described
for noroviruses, as follows: [(OD with urea)/(OD without
urea)] × 100) [11]. The avidity for all mAbs was highest for
the EBOV GP used during primary vaccination (Figure 2A).
The avidity of mAb S33 was higher for all GPs, compared
with avidities of the other mAbs. Interestingly, mAbs S12 and
S17 showed the highest avidity for RESTV, which was not
part of the immunization scheme. Surprisingly, while SUDV
was used as a vaccination boost, most mAbs, except mAb S33,
did not have high avidity for this antigen.
To determine whether these 4 mAbs recognized the same
epitope, we determined inhibition of the binding of biotinylated
mAbs S3, S12, S17, and S33 to the EBOV GP by using the same
panel of unlabeled mAbs (at saturated concentrations). The
percentage of binding competition was calculated as [1− (OD com-
petition)/(OD maximum binding of biotinylated mAbs)] × 100,
as previously described for mAbs against SARS-CoV [12].
mAbs S12, S17, and S33 did not compete with S3; therefore,
S3 recognized a unique epitope on the GP (Figure 2B). mAbs
S12, S17, and S33 competed with both mAbs S12 and S17
with similar efﬁcacy. Surprisingly, although mAb S33 competed
with mAbs S12 and S17 in this assay, reciprocal competition
was not observed. The 1-directional competition between S33
and mAbs S12 and S17 suggests that these mAbs recognized
distinct epitopes that are close together, rather than overlap-
ping, on the GP. Unfortunately, several attempts to identify
the sequences of the conserved epitopes on the EBOV GP by
using a phage display peptide library were not successful
(data not shown).
Finally, an immunoﬂuorescence assay (IFA) found that none
of the mAbs detected EBOV infection in Vero cells by (data not
shown). The absence of EBOV-speciﬁc staining by IFA was
surprising, but the use of this technique under biosafety level
4 conditions requires ﬁxation of EBOV-infected cells with
10% formalin for 48 hours before samples can be transferred
to a biosafety level 2 facility and stained. This prolonged ﬁxation
has been shown to affect antigenicity.
Overall, these data show that conserved epitopes are present
on the GPs of all known Ebolavirus species. While the antibod-
ies described in this study did not display neutralizing activity,
nonneutralizing antibodies have been shown to protect in vivo
[7]. Therefore, future studies will include testing the in vivo
efﬁcacy of these mAbs to protect against lethal EBOV challenge.
In conclusion, we developed and performed an initial charac-
terization of a panel of broadly reactive mAbs against Ebolavirus
species. These mAbs will be crucial for the development of novel
point-of-care diagnostic assays that can detect viral antigen
during outbreaks of all known Ebolavirus species.
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Figure 2. The avidity (A) and competition (B) characteristics of 4 monoclonal antibodies was determined by an avidity or competitive enzyme-linked
immunosorbent assay, using the soluble glycoprotein of Bundibugyo virus (BDBV), Taï Forest virus (TAFV), Reston virus (RESTV), Sudan virus (SUDV),
and Ebola virus (EBOV) as antigens. Data are from 1 representative experiment of 3.
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